Iron mobilization, cytoprotection, and inhibition of cell proliferation in normal and transformed rat hepatocyte cultures by the hydroxypyridinone CP411, compared to CP20: A biological and physicochemical study

Biochemical Pharmacology

Volumn 67, Issue 8, 2004, Pages 1479-1487

  Gaboriau, François ^a   Chantrel Groussard, Karine ^a   Rakba, Nafissa ^a   Loyer, Pascal ^a   Pasdeloup, Nicole ^a   Hider, Robert C ^b   Brissot, Pierre ^a   Lescoat, Gérard ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antiproliferative effect; Cytoprotection; Desferrioxamine; DFO; FASII; Ferrous ammonium sulfate; Hepatocyte; Homovanillic acid; HVA; Hydroxypyridinone iron chelator; Lactate dehydrogenase; LDH; Non transferrin bound iron; NTBI; SAL; Salicylic acid; Ultraviolet C; UVC

Indexed keywords

CHELATING AGENT; COPPER; CP 411; DEFERIPRONE; DNA; HYDROXYL RADICAL; IRON; IRON 55; LACTATE DEHYDROGENASE; PYRIDONE DERIVATIVE; SCAVENGER; THYMIDINE; UNCLASSIFIED DRUG; ZINC;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL PROTECTION; CELL TRANSFORMATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; DNA CONTENT; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG STABILITY; DRUG UPTAKE; ENZYME RELEASE; EVALUATION; FENTON REACTION; FLOW CYTOMETRY; HEPATOMA CELL; INHIBITION KINETICS; IRON KINETICS; IRON OVERLOAD; LIPOPHILICITY; LIVER CELL; MALE; MASS SPECTROMETRY; MEASUREMENT; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; TIME; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELLS, CULTURED; CYTOPROTECTION; HEPATOCYTES; HYDROXYL RADICAL; IRON; IRON CHELATING AGENTS; MALE; MASS SPECTROMETRY; PIPERIDINES; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED;

EID: 1642300421     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.12.019     Document Type: Article

References (45)

1. McCance R.A., Widdowson E.M. Absorption and excretion of iron. Lancet. ii:1937;680-684.
2. Deugnier Y., Charalambous P., Le Quilleuc D., Turlin B., Searle J., Brissot P., Powell L.W., Halliday J.W. Preneoplastic significance of hepatic iron-free foci in genetic hemochromatosis: a study of 185 patients. Hepatology. 18:1993;1363-1369.
3. Hsing A.W., McLaughlin J.K., Olsen J.H., Mellemkjar L., Wacholder S., Fraumeni J.F. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int. J. Cancer. 60:1995;160-162.
4. Chenoufi N., Loréal O., Drénou B., Cariou S., Hubert N., Leroyer P., Brissot P., Lescoat G. Iron may induce DNA synthesis and repair in rat hepatocytes stimulated by EGF/pyruvate. J. Hepatol. 26:1995;650-658.
5. Hann H.W.L., Stahlhut M.W., Blumberg B.S. Iron nutrition and tumor growth: decreased tumor growth in iron deficient mice. Cancer Res. 48:1988;4168-4170.
6. Thompson H.J., Kennedy K., Witt M., Juzefyk J. Effect of dietary iron deficiency or excess on the induction of mammary carcinogenenis by 1-methyl-1-nitrosourea. Carcinogenesis. 12:1991;111-114.
7. Tarao K., Shimizu A., Ohkawa S., Harada M., Ito Y., Tamai S., Kuni Y., Okamoto N., Inoue T., Kanisawa M. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology. 103:1992;595-600.
8. Ballardini G., Groff P., Zoli M., Bianchi G., Giostra F., Francesconi R., Lenzi M., Zauli D., Cassani F., Bianchi F. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J. Hepatol. 20:1994;218-222.
9. Soyano A., Chinea M., Romano E.L. The effect of desferrioxamine on the proliferative response of rat lymphocytes stimulated with various mitogens in vitro. Immunopharmacology. 8:1984;163-169.
10. Polson R.J., Jenkins R., Lombard M., Williams A.C., Roberts S., Nouri-Aria K., Williams R., Bomford A. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology. 71:1990;176-181.
11. Richardson D.R., Milnes K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: the mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood. 89:1997;3025-3038.
12. Chenoufi N., Baffet G., Drénou B., Cariou S., Desille M., Clément B., Brissot P., Lescoat G., Loréal O. Deferoxamine arrests in vitro the proliferation of porcine hepatocyte in G1 phase of the cell cycle. Liver. 18:1997;60-67.
13. Chenoufi N., Drénou B., Loréal O., Pigeon C., Brissot P., Lescoat G. Antiproliferative effect of deferiprone on the HepG2 cell line. Biochem. Pharmacol. 56:1998;431-437.
14. Rakba N., Loyer P., Gilot D., Delcros J.G., Glaise D., Baret P., Pierre J.L., Brissot P., Lescoat G. Antiproliferative and apoptotic effects of O-Trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis. 21:2000;943-951.
15. Reddel R.R., Hedley D.W., Sutherland R.L. Cell cycle effects of iron depletion on T-47D human breast cancer cells. Exp. Cell Res. 161:1985;277-284.
16. Hoyes K.P., Hider R.C., Porter J.B. Cell cycle synchronisation and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. Cancer Res. 52:1992;4591-4599.
17. Kulp K.S., Green S.L., Vulliet P.R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res. 229:1996;60-68.
18. Hileti D., Panayiotidis P., Hoffbrand A.V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89:1995;181-187.
19. Kovar J., Stunz L.L., Stewart B.C., Kriegerbeckova K., Ashman R.F., Kemp J.D. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology. 65:1997;61-68.
20. Brodie C., Siriwardana G., Lucas J., Schleicher R., Terada N., Szepesi A., Gelfand E., Seligman P. Neuroblastoma sensitivity to growth inhibition by desferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 53:1993;3968-3975.
21. Glickstein H., Breuer W., Loyevsky M., Konijn A.M., Shanzer A., Cabantchik Z.I. Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells. Blood. 87:1996;4871-4878.
22. Valle P., Timeus F., Piglione M., Rosso P., di Montezemolo L.C., Crescenzio N., Marranca D., Ramenghi U. Effect of different exposures to desferrioxamine on neuroblastoma cell lines. Pediatr. Hematol. Oncol. 12:1995;439-446.
23. Olivieri N.F., Koren G., Matsui D., Liu P.P., Blendis L., Cameron R., McClelland R.A., Templeton D.M. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 79:1992;2741-2748.
24. Al-Refaie F.N., Wonke B., Hoffbrand A.V., Wickens D.G., Nortey P., Kontoghiorges G.J. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood. 80:1992;593-599.
25. Collins A.F., Fassos F.F., Stobie S., Lewis N., Shaw D., Fry M., Templeton D.M., McClelland R.A., Koren G., Olivieri N.F. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4- one (L1) in iron-loaded patients with sickle cell disease. Blood. 83:1994;2329-2333.
26. Chenoufi N., Hubert N., Loréal O., Morel I., Pasdeloup N., Cillard J., Brissot P., Lescoat G. Inhibition of iron toxicity in rat and human hepatocyte cultures by the hydroxypyridin-4-ones CP20 and CP94. J. Hepatol. 23:1995;166-173.
27. 2+ on enzymatic dispersion of isolated perfused liver. Exp. Cell Res. 74:1972;450-454.
28. Guguen C., Guillouzo A., Boisnard M., Le Cam A., Bourel M. Etude ultrastructurale de monocouches d'hépatocytes de rat cultivés en présence d'hémisuccinate d'hydrocortisone. Gastroenterol. Biol. 8:1975;223-231.
29. Deschatrette J., Weiss M.C. Characterization of differentiated clones from a rat hepatoma. Biochimie. 56:1974;1603-1611.
30. Dobbin P.S., Hider R.C., Hall A.D., Taylor P.D., Sarpong P., Porter J.B., Xiao G., van der Helm D. Synthesis, physicochemical properties and biological evaluation of N-substituted 2-alkyl-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 36:1993;2448-2458.
31. Gaboriau F., Delcros J.G., Moulinoux J.P. A simple assay for the measurement of plasma antioxidant status using spontaneous autoxidation of homovanillic acid. J. Pharmacol. Toxicol. 47:2002;33-43.
32. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
33. Hider R.C. Nature of nontransferrin-bound iron. Eur. J. Clin. Invest. 32:2002;50-54.
34. Halliwell B., Gutteridge J.M. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch. Biochem. Biophys. 246:1986;501-514.
35. De Silva D.M., Askwith C.C., Kaplan J. Molecular mechanisms of iron uptake in eukaryotes. Physiol. Rev. 76:1996;31-47.
36. Brissot P., Wright T.L., Ma W.L., Weisiger R. Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J. Clin. Invest. 76:1985;1463-1470.
37. Wright T.L., Brissot P., Ma W.L., Weisiger R.A. Characterisation of non-transferrin-bound iron clearance by rat liver. J. Biol. Chem. 261:1986;10909-10914.
38. Deugnier Y., Guyader D., Crantok L., Lopez J.M., Turlin B., Yaouang J., Jouanolle H., Campion J.P., Launois B., Halliday J.W., Powell L.W., Brissot P. Primary liver cancer in genetic hemochromatosis: a clinical, pathological and pathogenetic study of 54 cases. Gastroenterology. 1104:1993;228-234.
39. Turlin B., Deugnier Y. Iron overload disorders. Clin. Liver Dis. 6:2002;481-496.
40. Baker E., Wong A., Peter H., Jacobs A. Desferrithiocin is an effective iron chelator in vitro and in vivo but ferrithiocin is toxic. Br. J. Haematol. 81:1992;424-431.
41. Rakba N., Aouad F., Henry C., Caris C., Morel I., Baret P., Pierre J.L., Brissot P., Ward R.J., Lescoat G., Crichton R. Iron mobilisation and cellular protection by a new synthetic chelator O-Trensox. Biochem. Pharmacol. 55:1998;1797-1806.
42. Henry C., Rakba N., Imbert D., Thomas F., Baret P., Serratrice G., Gaude D., Pierre J.L., Ward R.J., Crichton R.R., Lescoat G. New 8-hydroxyquinoleine and cathecolate iron chelators: influence of their partition coefficient on their biological activity. Biochem. Pharmacol. 62:2001;1355-1362.
43. Porter J.B., Gyparaki M., Burke L., Huehns E.R., Sarpong P., Saez V., Hider R.C. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood. 72:1988;1497-1503.
44. Zanninelli G., Glickstein H., Breuer W., Milgram P., Brissot P., Hider R.C., Konijn A.M., Libman J., Shanzer A., Cabantchik Z.I. Chelation and mobilization of cellular iron by different classes of chelators. Mol. Pharmacol. 51:1997;842-852.
45. Meyer-Brunot H.G., Keberle H. Biliary excretion of ferrioxamines of varying liposolubility in perfused rat liver. Am. J. Physiol. 214:1968;1193-1200.